SECURITIES AND EXCHANGE COMMISSION  
                            Washington, D.C.  20549  
                       ___________________________________  
  
                                    FORM 10-K/A
                                  Amendment NO. 2  
                                    (Mark one)  
  
[X] Annual report pursuant to Section 13 or 15(d) of the Securities 
Exchange Act of 1934 for the fiscal year ended March 31, 1997 
  
                                      OR  
  
[ ] Transition report pursuant to Section 13 or 15(d) of the Securities   
Exchange Act of 1934 for the transition period from __________ to 
________  
  
                            Commission File No. 0-15360  
  
                       BIOJECT MEDICAL TECHNOLOGIES INC.  
           (Exact name of registrant as specified in its charter)  
  
    Oregon                                       93-1099680  
(State of other jurisdiction of                (I.R.S. identification 
 incorporation or organization)                 employer no.)  
  
   7620 SW Bridgeport Road  
     Portland, Oregon                            97224  
(Address of principal executive offices)       (Zip code)  
  
                        (503) 639-7221  
    (Registrant's telephone number, including areas code)  
  
  Securities registered pursuant to Section 12(b) of the Act:  
  
    Title of each class           Name of each exchange on which       
                                  registered  
        None                                None  
  
   Securities registered pursuant to Section 12(g) of the Act:  
                             Title of Class  
                      Common Stock, no par value  
  
     Indicate by check mark whether the registrant (1) has filed all 
reports required to be filed by Section 13 or 15(d) of the Securities 
Exchange Act of 1934 during the preceding 12 months (or for such shorter 
period that the registrant was required to file such reports), and (2) 
has been subject to such filing requirements for the past 90 days.  Yes 
[X]   No [ ]  
  
     Indicate by check mark if disclosure of delinquent filers pursuant 
to Item 405 of Regulation S-K is not contained herein, and will not be   
contained, to the best of registrants knowledge, in definitive proxy or 
information  statements incorporated by reference in Part III of this 
Form 10-K or any  amendment to this Form 10-K. [ ]   
     
     State the aggregate market value of voting stock held by non-
affiliates of the registrant, as of May 31, 1997: $17,660,800  
  
     Indicate the number of shares outstanding of each of the 
registrant's classes of common stock, as of May 31, 1997:  Common Stock, 
no par value, 19,540,413 shares.  

Documents Incorporated by Reference:  
  
Portions of the registrant's definitive Proxy Statement for the 1997 
Annual Shareholders' Meeting are incorporated by reference into 
Part III  



PART II  
  
Item 5. MARKET FOR THE REGISTRANT'S COMMON EQUITY AND 
RELATED STOCKHOLDER MATTERS  
  
The Company's Common Stock is traded on the NASDAQ National Market   
under the Symbol "BJCT."  The following table sets forth the high and 
low closing sale prices of the Company's Common Stock on the NASDAQ 
National Market.

         

           
                                                 High       Low  
                                                 _____     _____  
                                                                
                                                     
Fiscal year Ended March 31, 1995:  
  
   First Quarter                                 $3.00     $2.00  
   Second Quarter                                 4.13      3.25  
   Third Quarter                                  3.63      2.81  
   Fourth Quarter                                 2.50      1.50  
  
Fiscal Year Ended March 31, 1996:  
  
   First Quarter                                  3.00      1.44  
   Second Quarter                                 2.97      1.19  
   Third Quarter                                  2.81      1.81  
   Fourth Quarter                                 1.94      1.25  

Fiscal Year Ended March 31, 1997:  
  
   First Quarter                                  1.41      1.28
   Second Quarter                                 1.03      0.97
   Third Quarter                                  0.78      0.75
   Fourth Quarter                                 0.78      0.63

          
  
The closing sale price on May 30, 1997, as reported on the NASDAQ 
National Market, was $0.91 per share.  The Company has declared no 
dividends during its history and has no intention of declaring a 
dividend in the foreseeable future. As of May 30, 1997 the number of 
shareholders of record of the Company's Common Stock was 1,423.  


                         SIGNATURE
  
Pursuant to the requirements of Section 13 or 15(d) of the  
Securities Exchange Act of 1934, Bioject Medical Technologies  
Inc. has duly caused this report to be signed on its behalf by  
the undersigned, thereunto duly authorized:  
  
        BIOJECT MEDICAL TECHNOLOGIES INC.  
        (Registrant)  
  
  
        By: /S/ PEGGY J. MILLER  
        Peggy J. Miller  
        Vice President, Chief Financial   
        Officer, Secretary/Treasurer